EMA Application withdrawn: Qizenday — Medday Pharmaceuticals

View source ↗

Summary

EMA withdrawal of the Qizenday application from Medday Pharmaceuticals for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Qizenday

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Sclerosis. MAH: Medday Pharmaceuticals. Decision date: 15/12/2017